Thursday, May 26, 2016 4:39:37 PM
By Lydia Ramsey 52m ago
Click For BusinessInsider Article
A tiny matchstick-size implant called Probuphine could help address some of the toughest parts of treating addiction.
The implant, an inch long and the width of a matchstick, is designed to deliver the drug buprenorphine to people suffering from opioid painkiller addiction continuously for six months. It's the first implanted opioid addiction treatment to be approved by the FDA.
Buprenorphine is an opioid that appears to work by activating the receptors in the brain that respond to opiates like prescription pain medications and heroin. It is designed to create a sealing effect over those receptors so that an addicted person doesn't crave getting high to the same extreme. This would ideally cut down the person's desire for the drug.
The implant was approved four months after an advisory committee recommended it, but the final decision was delayed three more months to give the agency time to get a more complete picture of its technology and roll-out plan. Part of that plan involves training doctors, Braeburn Pharmaceuticals CEO Behshad Sheldon told Business Insider.
Sheldon said she expects training on how to implant the device to begin as soon as Memorial Day weekend, with the devices launching for use in patients by June 21.
Sticking with treatment
According to the Centers for Disease Control and Prevention, only about half of all people who take any kind of medication do so in the way that's actually prescribed. About 20% to 30% of people never fill their prescriptions in the first place, and others simply forget to take it or choose not to.
That's a big problem not only when it comes to chronic diseases, which need constant and consistent management, but in particular with conditions that are pain-related and require treatment with powerful painkillers which can be addictive.
Over time, most people develop a steady tolerance for opioid painkillers, meaning they more of the drug to get the same effect. If they stop taking the medication regularly, that tolerance goes down. This can be dangerous: If an addicted person who's managed to stop using a drug for a long period of time takes it again, he or she can overdose fairly easily and die. This is what contributes to higher rates of overdose in many addicts, according to the National Institute for Drug Abuse.
This is one of the ideas fueling Braeburn's implant. "If you make a mistake, because opioid dependence is so unforgiving as a disease, one mistake could kill you," Sheldon said.
Another concern is that buprenorphine is often misused by people who are not opioid dependent to get high. The hope is that an implant would make that more difficult.
Concerns about cost
The implant won't necessarily be cheap, though Sheldon said it would be priced lower than other long-acting drugs used in the neuropsychological space. Braeburn is also working with payors to come up with an "outcome-based agreement" that will give them rebates if Probuphine doesn't save them money, compared to other buprenorphine options.
This is Braeburn's first drug approval. Beyond that, the company is looking into injectable versions of buprenorphine taken weekly or monthly that could bridge the massive gap between taking a pill once a day and a six-month-long treatment plan. That way, the doctor can better monitor the recovery in its early stages, a concern heard at the advisory committee meeting for the implant.
Blessings to All
TRUTH
I've never claimed to have all the answers but feel i'm beginning to corner the market in questions worthy of them.
Recent TTNP News
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 12:32:38 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/19/2024 08:23:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:22:56 PM
- Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. • GlobeNewswire Inc. • 08/19/2024 08:11:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/15/2024 01:29:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 01:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM